About 5'-AMP-activated protein kinase subunit beta-1
5'-AMP-activated protein kinase subunit beta-1 (PRKAB1) is a protein
from Homo sapiens identified by UniProt accession
Q9Y478, 270 residues long.
MolForge cross-references it against 0 known binders and
607 disease associations.
Target properties
| Protein name | 5'-AMP-activated protein kinase subunit beta-1 |
|---|
| UniProt accession | Q9Y478 |
|---|
| Gene | PRKAB1 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 270 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Approved drugs hitting this target (2)
DrugCentral-linked approved drugs that act on this protein.
Disease associations (607)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.47
- lysosomal storage disease · score 0.34
- multiple sclerosis · score 0.34
- Parkinson disease · score 0.34
- Alzheimer disease · score 0.34
- basophil count · score 0.31
- neutrophil count · score 0.30
- breast adenocarcinoma · score 0.29
- leukocyte count · score 0.28
- lung adenocarcinoma · score 0.28
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q9Y478-F1 | alphafold | PREDICTED | 77.72 | — |
Amino-acid sequence (270 residues)
MGNTSSERAA LERHGGHKTP RRDSSGGTKD GDRPKILMDS PEDADLFHSE EIKAPEKEEF LAWQHDLEVN DKAPAQARPT VFRWTGGGKE VYLSGSFNNW SKLPLTRSHN NFVAILDLPE GEHQYKFFVD GQWTHDPSEP IVTSQLGTVN NIIQVKKTDF EVFDALMVDS QKCSDVSELS SSPPGPYHQE PYVCKPEERF RAPPILPPHL LQVILNKDTG ISCDPALLPE PNHVMLNHLY ALSIKDGVMV LSATHRYKKK YVTTLLYKPI
Explore 5'-AMP-activated protein kinase subunit beta-1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets